We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

D’oh!

29 May 2012 By Robert Cyran

The biotech firm’s value plunged 18 pct after it admitted a basic statistics mistake, confusing relative with absolute improvement for a new drug combination for cystic fibrosis. Such a bone-headed error is careless, but comical rather than fatal. The share slump looks overdone.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)